Stifel bumps Nvidia stock target, sees attractive valuation
Andrew Callos, the Executive Vice President and Chief Commercial Officer at Cytokinetics Inc. (NASDAQ:CYTK), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On March 14, 2025, Callos sold 100 shares of common stock at a price of $45.00 per share, totaling $4,500. The transaction occurred with CYTK trading near $44.36, slightly above what InvestingPro analysis suggests is Fair Value.
Additionally, Callos acquired 100 shares through the exercise of stock options at a price of $23.26 per share. This exercise added $2,326 to his holdings, which now total 37,663 shares of common stock. The transactions were conducted under a pre-arranged trading plan. With a market capitalization of $5.2 billion and analyst targets ranging from $60 to $120, InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about CYTK’s financial health and market position.
In other recent news, Cytokinetics reported its fourth-quarter 2024 earnings, revealing a slight miss in earnings per share, posting an EPS of -$1.26 against a forecast of -$1.22. However, the company’s revenue of $16.9 million showed significant year-over-year growth from $1.7 million. Morgan Stanley (NYSE:MS) upgraded Cytokinetics to an Overweight rating with a $67 price target, anticipating significant developments, including the potential approval of aficamten for obstructive hypertrophic cardiomyopathy (HCM). The firm expects aficamten to receive approval within the year, positioning it as a first-line therapy. Meanwhile, Citi maintained its Buy rating on Cytokinetics, setting a price target of $86 and noting the FDA’s decision not to hold an advisory committee meeting for aficamten’s review. Cytokinetics is preparing for a potential U.S. commercial launch of aficamten in September 2025, with plans to expand its commercial infrastructure in Europe and China through partnerships. The company also provided its financial guidance for 2025, projecting GAAP operating expenses between $670 million and $710 million. These developments are being closely monitored by investors, as they could significantly impact Cytokinetics’ market position and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.